Get the Stockscreener App
1.40
3.45%
-0.05
Acumen Pharmaceuticals Inc stock is traded at $1.40, with a volume of 244.66K.
It is down -3.45% in the last 24 hours and down -15.15% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
See More
Previous Close:
$1.45
Open:
$1.45
24h Volume:
244.66K
Relative Volume:
0.81
Market Cap:
$84.11M
Revenue:
-
Net Income/Loss:
$-64.86M
P/E Ratio:
-1.25
EPS:
-1.12
Net Cash Flow:
$-55.66M
1W Performance:
+2.19%
1M Performance:
-15.15%
6M Performance:
-50.53%
1Y Performance:
-57.32%
1-Day Range:
$1.39
$1.465
1-Week Range:
$1.3685
$1.52
52-Week Range:
$1.2817
$5.09
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
925-368-8508
Address
427 PARK ST., CHARLOTTESVILLE
Compare ABOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.40 | 84.11M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.76 | 121.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
685.66 | 74.96B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
640.14 | 38.90B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.51 | 32.43B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.58 | 28.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Acumen stock touches 52-week low at $1.54 amid market challenges - MSN
Acumen Pharmaceuticals CEO O'Connell sells shares worth $20,102 - MSN
Acumen Pharmaceuticals COO Barton Russell sells shares worth $4,692 - MSN
SG Americas Securities LLC Grows Stock Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
ABOS stock touches 52-week low at $1.31 amid market challenges - MSN
ABOS stock touches 52-week low at $1.31 amid market challenges By Investing.com - Investing.com South Africa
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - MarketBeat
Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results - cnhinews.com
JPMorgan Chase & Co. Has $156,000 Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
ABOS stock touches 52-week low at $1.52 amid market challenges - Investing.com India
ABOS stock touches 52-week low at $1.52 amid market challenges By Investing.com - Investing.com South Africa
Acumen Pharmaceuticals chief medical officer sells $5,118 in shares - MSN
Acumen Pharmaceuticals chief legal officer sells shares worth $5,434 - MSN
Matt Zuga Sells 28,902 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Daniel Joseph Oconnell Sells 12,619 Shares - MarketBeat
Acumen Pharmaceuticals CFO sells shares totaling $56,619 - MSN
Analysts Set Expectations for ABOS FY2025 Earnings - Defense World
Acumen Pharmaceuticals CFO sells shares totaling $56,619 By Investing.com - Investing.com South Africa
Acumen Pharmaceuticals CEO O'Connell sells shares worth $20,102 By Investing.com - Investing.com Canada
Brokers Offer Predictions for ABOS FY2025 Earnings - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock Holdings Lifted by Barclays PLC - Defense World
Acumen Pharmaceuticals chief medical officer sells $5,118 in shares By Investing.com - Investing.com Nigeria
Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Expands By 9.1% - Defense World
Acumen stock touches 52-week low at $1.54 amid market challenges By Investing.com - Investing.com South Africa
ABOS stock touches 52-week low at $1.68 amid market challenges - Investing.com
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings - The Manila Times
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of - The Bakersfield Californian
Acumen's Alzheimer's Drug Shows Promise: Phase 1 Trial Reveals Strong Safety Profile, Plaque Reduction - StockTitan
Acumen Pharmaceuticals CFO Zuga Matt sells $24,366 in stock By Investing.com - Investing.com Australia
Acumen Pharmaceuticals' chief legal officer sells $20,505 in stock By Investing.com - Investing.com Australia
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Shares Purchased by Geode Capital Management LLC - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Shares Bought by Barclays PLC - Defense World
Acumen Pharmaceuticals chief medical officer sells $20,046 in stock By Investing.com - Investing.com Nigeria
Acumen Pharmaceuticals COO Barton Russell sells $14,225 in stock - Investing.com India
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) COO Sells 7,636 Shares - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Insider Eric Siemers Sells 10,859 Shares - MarketBeat
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Sells $87,911.52 in Stock - MarketBeat
Acumen Pharmaceuticals COO Barton Russell sells $14,225 in stock By Investing.com - Investing.com Nigeria
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
3.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):